^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastrointestinal Cancer |
| Drug: | erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) + anbenitamab (KN026) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Excerpt:
...- Histologically or cytologically confirmed, locally advanced HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma....
Trial ID:
Source:
Title:
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Excerpt:
...Cohorts A and B: Histologically confirmed unresectable HER2-positive metastatic colorectal cancer, meeting the following criteria: a) Previously untreated with systemic anti-tumor therapy, or the time from (neo)adjuvant chemotherapy completion to disease recurrence > 6 months; b) Gene sequencing shows wild-type RAS and BRAF (participants' previous KRAS and BRAF test results are acceptable)....
Trial ID:
Less C2 evidence
Source:
Title:
1377P - Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors
Published date:
09/13/2021
Excerpt:
ORR in the late line GI cancer cohort was 44% (8/18, 95% CI: 22%-69%). Median PFS was 5.8 months (mo). 6- and 12-month OS rates were 89.1% and 71.3%....KN026 combined with KN046 as a chemo-free regimen was safe and demonstrated potential superior clinical benefit to available standard of care in both treatment-naive and heavily pretreated HER2-postive gastrointestinal tumors.
Trial ID:
